Document Detail


Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study.
MedLine Citation:
PMID:  18698212     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The renin-angiotensin system and endothelial function have both been associated with hypertension. The aim of the present study was to assess the relationship of six previously characterized gene variants in the renin-angiotensin system and the NOS3 gene with blood pressure progression and incident hypertension.
METHODS: We analyzed data from 18 436 Caucasian women who participated in a prospective cohort study and were free of hypertension at baseline. Six previously characterized single nucleotide polymorphisms (NOS3 rs1800779, NOS3 rs3918226, NOS3 rs1799983, ACE rs1799752, AGT rs699, and AGTR1 rs5186) were genotyped. Blood pressure progression at 48 months and incident hypertension during the entire follow-up according to the different genotypes and inferred haplotypes were assessed by logistic regression and Cox proportional hazards models, respectively.
RESULTS: At 48 months, 47.4% of the women had blood pressure progression. The odds ratios (95% confidence intervals) for blood pressure progression associated with NOS3 rs1800779, NOS3 rs3918226, NOS3 rs1799983, ACE rs1799752, AGT rs699, and AGTR1 rs5186 were 1.00 (0.96-1.05), 1.00 (0.92-1.09), 0.99 (0.94-1.04), 0.96 (0.92-1.01), 1.04 (0.99-1.08), and 1.03 (0.98-1.08), respectively. During 9.8 years of follow-up, 29.6% of women developed incident hypertension. The hazard ratios (95% confidence interval) for the six polymorphisms were 1.01 (0.97-1.06), 1.06 (0.99-1.14), 1.05 (1.01-1.09), 0.99 (0.95-1.02), 1.01 (0.97-1.05), and 0.99 (0.95-1.04). NOS3 haplotypes were not significantly associated with blood pressure progression (P = 0.91) or incident hypertension (P = 0.10).
CONCLUSION: Blood pressure progression and incident hypertension are not consistently associated with six well-characterized genetic polymorphisms of the renin-angiotensin system and the NOS3 gene in a large cohort of Caucasian women.
Authors:
David Conen; Robert J Glynn; Julie E Buring; Paul M Ridker; Robert Y L Zee
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  26     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-08-13     Completed Date:  2008-12-19     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  1780-6     Citation Subset:  IM    
Affiliation:
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA. conend@uhbs.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensinogen / genetics
Antioxidants / therapeutic use
Aspirin / therapeutic use
Blood Pressure / genetics*
Cyclooxygenase Inhibitors / therapeutic use
Disease Progression
Female
Gene Frequency
Genetic Predisposition to Disease / epidemiology
Haplotypes
Humans
Hypertension, Renal / epidemiology*,  genetics*,  prevention & control
Incidence
Middle Aged
Nitric Oxide Synthase Type III / genetics*
Peptidyl-Dipeptidase A / genetics
Polymorphism, Single Nucleotide
Prospective Studies
Receptor, Angiotensin, Type 1 / genetics
Renin-Angiotensin System / genetics*
Risk Factors
Vitamin E / therapeutic use
Grant Support
ID/Acronym/Agency:
CA 47988/CA/NCI NIH HHS; HL 43851/HL/NHLBI NIH HHS; R01 CA047988/CA/NCI NIH HHS; R01 CA047988-09/CA/NCI NIH HHS; R01 HL043851/HL/NHLBI NIH HHS; R01 HL043851-09/HL/NHLBI NIH HHS; R01 HL043851-10/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Cyclooxygenase Inhibitors; 0/Receptor, Angiotensin, Type 1; 11002-13-4/Angiotensinogen; 1406-18-4/Vitamin E; 50-78-2/Aspirin; EC 1.14.13.39/NOS3 protein, human; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 3.4.15.1/Peptidyl-Dipeptidase A
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determinants of kidney function in Swedish families: role of heritable factors.
Next Document:  Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by alis...